IQVIA (NYSE:IQV) Reaches New 52-Week High – What’s Next?

IQVIA Holdings Inc. (NYSE:IQV)’s stock price reached a new 52-week high on Wednesday . The company traded as high as $262.51 and last traded at $260.3030, with a volume of 53550 shares trading hands. The stock had previously closed at $259.42.

Wall Street Analyst Weigh In

Several research analysts recently commented on IQV shares. Morgan Stanley reaffirmed an “equal weight” rating and issued a $200.00 target price (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Royal Bank Of Canada upped their price objective on shares of IQVIA from $221.00 to $247.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. HSBC reiterated a “buy” rating and set a $240.00 target price on shares of IQVIA in a report on Monday, July 6th. Finally, Barclays restated an “overweight” rating on shares of IQVIA in a report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $241.88.

IQVIA Trading Up 0.5%

The stock’s 50-day simple moving average is $216.59 and its 200-day simple moving average is $188.02. The firm has a market capitalization of $42.92 billion, a PE ratio of 32.31, a P/E/G ratio of 2.21 and a beta of 1.18. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The company had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. During the same quarter in the previous year, the company earned $2.81 earnings per share. IQVIA’s quarterly revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA declared that its board has approved a share buyback plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to buy up to 6.8% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.

Insider Transactions at IQVIA

In other IQVIA news, insider W Richard Staub sold 5,500 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the completion of the transaction, the insider owned 13,312 shares of the company’s stock, valued at approximately $3,097,436.16. This trade represents a 29.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Bhavik Patel sold 1,855 shares of the business’s stock in a transaction on Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the sale, the insider owned 1,348 shares in the company, valued at approximately $317,143.96. This trade represents a 57.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 12,913 shares of company stock valued at $3,098,793. Company insiders own 1.70% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. California State Teachers Retirement System increased its stake in shares of IQVIA by 18,735.4% during the second quarter. California State Teachers Retirement System now owns 49,241,537 shares of the medical research company’s stock valued at $9,514,450,000 after purchasing an additional 48,980,106 shares in the last quarter. BlackRock Inc. bought a new position in IQVIA during the 2nd quarter valued at approximately $2,811,292,000. Boston Partners purchased a new position in IQVIA during the third quarter valued at $676,698,000. Norges Bank purchased a new stake in shares of IQVIA in the fourth quarter worth $497,445,000. Finally, Victory Capital Management Inc. increased its holdings in shares of IQVIA by 2,628.1% during the fourth quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock valued at $377,670,000 after acquiring an additional 1,614,063 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.